Michelle Gayari

Michelle Gayari, Executive Vice President, Global Operational Excellence and Innovation and member of the Executive Team at MMS, leads the global technical, medical and scientific functions. She has more than 20 years of experience in clinical research, including career highlights at the Mayo Clinic and Pfizer, prior to joining MMS.

Michelle’s long tenure in the data service area and commitment to excellence, fosters a culture across our global offices that attracts the best talent. Her global operational teams are responsible for all elements of clinical trial data strategies and tech-enabled services, including specialized expertise in all data and summarization steps leading to successful NDA submissions globally. Michelle established a Center of Excellence within the global operational teams that bring value beyond the deliverable, emphasizing strong science and process. Metrics and a strong emphasis on service delivery methodology drive the organization. Her teams lend their expertise to client sponsors ensuring the highest level of customer satisfaction and return on their investment.

The growth that MMS has experienced since day one is truly due to the people in our offices across the world. We’ve been able to not only develop highly talented professionals but we play a critical role in the process of bringing life altering drugs to market. I like to say that “good work rises to the top,” and I am continually reminded of that every day.
Michelle Gayari
Executive Vice President, Global Operational Excellence and Innovation

She earned her BS in Statistics, Mathematics, and Psychology from Central Michigan University. Michelle’s commitment to mentoring and education extends to the community, including a board position on T.E.A.C.H. and continued expansion of MMS Academy curriculum.

Suggested For You

perspectives

November 21st, 2024

Essential Nonclinical Strategies for Cell and Gene Therapy (CGT) Success

news

November 19th, 2024

MMS Recognized as a Top Workplace by Detroit Free Press and USA Today Network for the Fourth Consecutive Year

perspectives

November 12th, 2024

REMS Logic Modeling: Applying FDA Guidance from November 2024 CDER Webinar

news

November 8th, 2024

MMS Named a Finalist in the 2024 Fierce CRO Awards for Leadership in Regulatory Compliance

perspectives

November 6th, 2024

How to Successfully Manage Rescue Studies and Turn Around Clinical Trials Facing Failure

perspectives

October 29th, 2024

Why Outsourcing QC of Regulatory and Medical Writing Documents is a Competitive Advantage for Large Pharma Companies

perspectives

October 22nd, 2024

Choosing the Right Clinical Trial Design: A Crucial Step in Protocol Development

perspectives

October 15th, 2024

Putting the Action in Diversity Action Plans and the Real-Time Data Visualization Technology Needed to Ensure It Happens

news

October 15th, 2024

MMS Recognized with EcoVadis Bronze Medal for Leadership in ESG Sustainability Efforts as a Leading Clinical Research Organization (CRO)

perspectives

October 8th, 2024

Diversity Action Plan Guidance Part I: Implications for Sponsors

webinar

October 22nd, 2024

Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules

perspectives

September 30th, 2024

Meet the Leaders Driving MMS’s European Growth